U.S. Markets close in 5 hrs 44 mins

Harvard Bioscience, Inc. (HBIO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.6800-0.0400 (-1.08%)
As of 04:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.7200
Bid3.0000 x 1100
Ask3.6900 x 1400
Day's Range3.5800 - 3.7950
52 Week Range3.3600 - 8.7500
Avg. Volume204,059
Market Cap150.183M
Beta (5Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)-0.0470
Earnings DateMar 08, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks

    Harvard Bioscience (HBIO) Loses 35.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    Harvard Bioscience (HBIO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • Zacks

    Harvard Bioscience (HBIO) Q1 Earnings and Revenues Lag Estimates

    Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -20% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Harvard Bioscience Announces First Quarter 2022 Financial Results

    •Revenue up 7% year-over-year despite volatility in China related to COVID-19 and global supply chain headwinds HOLLISTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2022. Jim Green, Chairman and CEO, said, “Our revenue was up 7% on strength from North American sales despite the impact of lockdowns in China. Demand for our pre-clinical and cellular/molecular (CMT) products